EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE

Tonini, G; Loupakis, F; Berardi, R; Addeo, L; Ortega, C; Sabbatini, R; Venditti, O; Virzì, V Santini D

Risultato della ricerca: Paper

Abstract

Introduction. Bone metastases are an emerging clinical problem in colorectal cancer patients probably related to survival increase. There are no data in literature about the role of BPs in the treatment of bone disease from colorectal cancer. We present the final data of a large Italian multicenter retrospective analysis. Methods. 264 colorectal cancer patients with occurrence of bone metastases have been included in the study. All patients were dead due to cancer at the moment of the study inclusion. Patients characteristics, Skeletal Related Events (SRE) data and median survival after bone metastases appearance have been collected in a master data base and statistically analyzed. The primary efficacy endpoint was time to first SRE; secondary endpoint was median survival. 31 patients have been analysed as control group. Results. In 107 patients bisphosphonates data were not available. A total of 157 patients have been included for zoledronic efficacy analysis. A total of 126 patients received zoledronic acid (4 mg) via a 15-minute infusion every 4 weeks until performance status worsening or death. The median time to first SRE in the whole population was 2 mths (1.04-3.45). The median time to first SRE in the zoledronic treated patients was 3.168 mths (0.49- 2.19) compared with 1.71 mths (0.41-0.90) in the control group (p = 0.009). The median survival after skeletal progression was 7 mths (5.75-8.704). The median survival in the zoledronic treated group was 10 mths (8.08-11.91) compared with 6 mths (4.45- 7.54) (p = 0.161). Conclusions. Complete results of statistical analysis will be presented during the meeting. The present analysis represent the efficacy demonstration of a bisphosphonate in bone metastases from colorectal cancer patients. B13 LENOGRASTIM IN PREVENTING
Lingua originaleEnglish
Stato di pubblicazionePublished - 2010

Fingerprint

zoledronic acid
Colorectal Neoplasms
Bone and Bones
Survival
Diphosphonates
Neoplasm Metastasis
Bone Diseases

Cita questo

Tonini, G; Loupakis, F; Berardi, R; Addeo, L; Ortega, C; Sabbatini, R; Venditti, O; Virzì, V Santini D (2010). EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE.

EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE. / Tonini, G; Loupakis, F; Berardi, R; Addeo, L; Ortega, C; Sabbatini, R; Venditti, O; Virzì, V Santini D.

2010.

Risultato della ricerca: Paper

Tonini, G; Loupakis, F; Berardi, R; Addeo, L; Ortega, C; Sabbatini, R; Venditti, O; Virzì, V Santini D 2010, 'EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE'.
Tonini, G; Loupakis, F; Berardi, R; Addeo, L; Ortega, C; Sabbatini, R; Venditti, O; Virzì, V Santini D. EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE. 2010.
Tonini, G; Loupakis, F; Berardi, R; Addeo, L; Ortega, C; Sabbatini, R; Venditti, O; Virzì, V Santini D. / EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE.
@conference{d4f68117331b4f05873aa410ebefb7b9,
title = "EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE",
abstract = "Introduction. Bone metastases are an emerging clinical problem in colorectal cancer patients probably related to survival increase. There are no data in literature about the role of BPs in the treatment of bone disease from colorectal cancer. We present the final data of a large Italian multicenter retrospective analysis. Methods. 264 colorectal cancer patients with occurrence of bone metastases have been included in the study. All patients were dead due to cancer at the moment of the study inclusion. Patients characteristics, Skeletal Related Events (SRE) data and median survival after bone metastases appearance have been collected in a master data base and statistically analyzed. The primary efficacy endpoint was time to first SRE; secondary endpoint was median survival. 31 patients have been analysed as control group. Results. In 107 patients bisphosphonates data were not available. A total of 157 patients have been included for zoledronic efficacy analysis. A total of 126 patients received zoledronic acid (4 mg) via a 15-minute infusion every 4 weeks until performance status worsening or death. The median time to first SRE in the whole population was 2 mths (1.04-3.45). The median time to first SRE in the zoledronic treated patients was 3.168 mths (0.49- 2.19) compared with 1.71 mths (0.41-0.90) in the control group (p = 0.009). The median survival after skeletal progression was 7 mths (5.75-8.704). The median survival in the zoledronic treated group was 10 mths (8.08-11.91) compared with 6 mths (4.45- 7.54) (p = 0.161). Conclusions. Complete results of statistical analysis will be presented during the meeting. The present analysis represent the efficacy demonstration of a bisphosphonate in bone metastases from colorectal cancer patients. B13 LENOGRASTIM IN PREVENTING",
keywords = "bone metastasis, metastatic colon cancer",
author = "{Tonini, G; Loupakis, F; Berardi, R; Addeo, L; Ortega, C; Sabbatini, R; Venditti, O; Virz{\`i}, V Santini D} and Giuseppe Badalamenti",
year = "2010",
language = "English",

}

TY - CONF

T1 - EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE

AU - Tonini, G; Loupakis, F; Berardi, R; Addeo, L; Ortega, C; Sabbatini, R; Venditti, O; Virzì, V Santini D

AU - Badalamenti, Giuseppe

PY - 2010

Y1 - 2010

N2 - Introduction. Bone metastases are an emerging clinical problem in colorectal cancer patients probably related to survival increase. There are no data in literature about the role of BPs in the treatment of bone disease from colorectal cancer. We present the final data of a large Italian multicenter retrospective analysis. Methods. 264 colorectal cancer patients with occurrence of bone metastases have been included in the study. All patients were dead due to cancer at the moment of the study inclusion. Patients characteristics, Skeletal Related Events (SRE) data and median survival after bone metastases appearance have been collected in a master data base and statistically analyzed. The primary efficacy endpoint was time to first SRE; secondary endpoint was median survival. 31 patients have been analysed as control group. Results. In 107 patients bisphosphonates data were not available. A total of 157 patients have been included for zoledronic efficacy analysis. A total of 126 patients received zoledronic acid (4 mg) via a 15-minute infusion every 4 weeks until performance status worsening or death. The median time to first SRE in the whole population was 2 mths (1.04-3.45). The median time to first SRE in the zoledronic treated patients was 3.168 mths (0.49- 2.19) compared with 1.71 mths (0.41-0.90) in the control group (p = 0.009). The median survival after skeletal progression was 7 mths (5.75-8.704). The median survival in the zoledronic treated group was 10 mths (8.08-11.91) compared with 6 mths (4.45- 7.54) (p = 0.161). Conclusions. Complete results of statistical analysis will be presented during the meeting. The present analysis represent the efficacy demonstration of a bisphosphonate in bone metastases from colorectal cancer patients. B13 LENOGRASTIM IN PREVENTING

AB - Introduction. Bone metastases are an emerging clinical problem in colorectal cancer patients probably related to survival increase. There are no data in literature about the role of BPs in the treatment of bone disease from colorectal cancer. We present the final data of a large Italian multicenter retrospective analysis. Methods. 264 colorectal cancer patients with occurrence of bone metastases have been included in the study. All patients were dead due to cancer at the moment of the study inclusion. Patients characteristics, Skeletal Related Events (SRE) data and median survival after bone metastases appearance have been collected in a master data base and statistically analyzed. The primary efficacy endpoint was time to first SRE; secondary endpoint was median survival. 31 patients have been analysed as control group. Results. In 107 patients bisphosphonates data were not available. A total of 157 patients have been included for zoledronic efficacy analysis. A total of 126 patients received zoledronic acid (4 mg) via a 15-minute infusion every 4 weeks until performance status worsening or death. The median time to first SRE in the whole population was 2 mths (1.04-3.45). The median time to first SRE in the zoledronic treated patients was 3.168 mths (0.49- 2.19) compared with 1.71 mths (0.41-0.90) in the control group (p = 0.009). The median survival after skeletal progression was 7 mths (5.75-8.704). The median survival in the zoledronic treated group was 10 mths (8.08-11.91) compared with 6 mths (4.45- 7.54) (p = 0.161). Conclusions. Complete results of statistical analysis will be presented during the meeting. The present analysis represent the efficacy demonstration of a bisphosphonate in bone metastases from colorectal cancer patients. B13 LENOGRASTIM IN PREVENTING

KW - bone metastasis, metastatic colon cancer

UR - http://hdl.handle.net/10447/57322

M3 - Paper

ER -